Abstract: Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
Type:
Grant
Filed:
January 24, 2019
Date of Patent:
May 5, 2020
Assignees:
Editas Medicine, Inc., The Broad Institute Inc., Massachusetts Institute of Technology, University of Iowa Reseach Foundation
Abstract: The present invention provides a therapeutic agent comprising an antibody-recognition epitope (ARE) covalently bound to a tumor cell, wherein the ARE is bound to an antibody that is specific for the ARE, to form a tumor cell:ARE:antibody complex, and kits and methods of using these tumor cell:ARE:antibody complexes.
Abstract: Fluorine-containing phosphonates and phosphonic acids are described. The method of preparation is a reaction of trialkylphosphites with dihalodifluoromethanes or a reaction of the salts of dialkylphosphites with halodifluoromethylphosphonates. The corresponding phosphonic acids are prepared by hydrolysis of the phosphonates.